The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

2.

The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.

3.

Insurance Claim Denials for Preventive Care More Common in At-Risk Patients

4.

More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.

5.

An ancient signaling pathway and 20 years of research offer hope for rare cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot